Literature DB >> 8957477

Tumor angiogenesis in pheochromocytomas and paragangliomas.

Q Liu1, G Djuricin, E D Staren, P Gattuso, V E Gould, J Shen, T Saclarides, D B Rubin, R A Prinz.   

Abstract

BACKGROUND: Angiogenesis correlates with growth and likely metastases in several tumors. To determine whether it has a similar role in pheochromocytomas, immunohistochemical staining of factor VIII was done on the tumor tissue of 42 patients.
METHODS: Formalin-fixed, paraffin-embedded tissue was obtained from 29 women and 13 men with 24 primary adrenal and 18 extraadrenal pheochromocytomas. Patients were divided into two groups. Group 1 included 32 patients with benign pheochromocytomas, and group 2 included 10 patients with malignant tumors evidenced by capsular or vascular invasion (six), liver metastases (three), or periaortic lymph node metastases (one). Blood vessels highlighted by factor VIII staining of endothelial cells with labeled streptavidin-biotin were counted under light microscopy. Mean vessel count within a 10 mm2 micrometer disk was calculated under x100, x200, and x400 magnification fields.
RESULTS: There were no significant differences in patient age or clinical symptoms between the groups. The mean tumor size in group 2 of 8.8 +/- 5.3 cm was larger than the mean of 4.8 +/- 2.8 cm in group 1 (p < 0.005). The mean counts of vessels in the x100, x200, and x400 magnification fields were 102 +/- 48, 40 +/- 18, and 19 +/- 9 in group 1, and 203 +/- 77, 73 +/- 28, and 37 +/- 15 in group 2. The number of blood vessels in group 2 was significantly higher than in group 1 (p < 0.001) in each studied field.
CONCLUSIONS: In this study the number of tumor blood vessels correlated with the invasive behavior of pheochromocytomas. Tumor angiogenesis may be useful in determining the likelihood of malignant behavior in pheochromocytomas.

Entities:  

Mesh:

Year:  1996        PMID: 8957477     DOI: 10.1016/s0039-6060(96)80037-7

Source DB:  PubMed          Journal:  Surgery        ISSN: 0039-6060            Impact factor:   3.982


  14 in total

1.  Rationale for anti-angiogenic therapy in pheochromocytoma and paraganglioma.

Authors:  Judith Favier; Peter Igaz; Nelly Burnichon; Laurence Amar; Rossella Libé; Cécile Badoual; Frédérique Tissier; Jérôme Bertherat; Pierre-François Plouin; Xavier Jeunemaitre; Anne-Paule Gimenez-Roqueplo
Journal:  Endocr Pathol       Date:  2012-03       Impact factor: 3.943

Review 2.  Current and future therapeutic approaches for metastatic pheochromocytoma and paraganglioma: focus on SDHB tumors.

Authors:  J Matro; A Giubellino; K Pacak
Journal:  Horm Metab Res       Date:  2013-01-15       Impact factor: 2.936

Review 3.  Molecular genetic alterations in adrenal and extra-adrenal pheochromocytomas and paragangliomas.

Authors:  Hilde Dannenberg; Paul Komminoth; Winand N M Dinjens; Ernst Jan M Speel; Ronald R de Krijger
Journal:  Endocr Pathol       Date:  2003       Impact factor: 3.943

4.  Color-coded duplex endoscopic ultrasound of the adrenals.

Authors:  S Meyer; M-A von Mach; D Ivan; S Schäfer; N Habbe; B Kann; P H Kann
Journal:  J Endocrinol Invest       Date:  2008-10       Impact factor: 4.256

5.  Angiogenesis and vascular architecture in pheochromocytomas: distinctive traits in malignant tumors.

Authors:  Judith Favier; Pierre-François Plouin; Pierre Corvol; Jean-Marie Gasc
Journal:  Am J Pathol       Date:  2002-10       Impact factor: 4.307

6.  The significance of angiogenesis in malignant pheochromocytomas.

Authors:  Patrick P G M Rooijens; Ronald R de Krijger; H Jaap Bonjer; Frieda van der Ham; Alex L Nigg; Hajo A Bruining; Steven W J Lamberts; Erwin van der Harst
Journal:  Endocr Pathol       Date:  2004       Impact factor: 3.943

7.  Phase II trial of pazopanib in advanced/progressive malignant pheochromocytoma and paraganglioma.

Authors:  Sina Jasim; Vera J Suman; Camilo Jimenez; Pamela Harris; Kostandinos Sideras; Jill K Burton; Francis Paul Worden; Richard J Auchus; Keith C Bible
Journal:  Endocrine       Date:  2017-07-06       Impact factor: 3.925

Review 8.  Target therapy in metastatic pheochromocytoma: current perspectives and controversies.

Authors:  Amrallah A Mohammed; Ayman M El-Shentenawy; Mohamed A Sherisher; Hani M El-Khatib
Journal:  Oncol Rev       Date:  2014-09-23

9.  Role of VEGF-A and its receptors in sporadic and MEN2-associated pheochromocytoma.

Authors:  Carla Vaz Ferreira; Débora Rodrigues Siqueira; Mírian Romitti; Lucieli Ceolin; Beatriz Assis Brasil; Luise Meurer; Clarissa Capp; Ana Luiza Maia
Journal:  Int J Mol Sci       Date:  2014-03-26       Impact factor: 5.923

10.  Angiogenesis in Endocrine Neoplasms.

Authors:  Martin Jugenburg; Kalman Kovacs; Ivan Jugenburg; Bernd W. Scheithauer
Journal:  Endocr Pathol       Date:  1997       Impact factor: 4.056

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.